Consolidated Financial Highlights (₹ Crore)

| Particulars | Q1FY27 | Q4FY26 | Q1FY26 |

| Revenue from operations | 554 | 602 | 496 |

| Other income | 4 | 3 | 6 |

| Total income | 558 | 605 | 502 |

| EBITDA | 148 | 189 | 125 |

| EBITDA Margin | 27% | 31% | 25% |

| Profit before tax | 98 | 139 | 81 |

| Tax expense | 25 | 35 | 20 |

| Profit after tax | 73 | 104 | 60 |

Key Financial Observations:

  • Q1 FY27 revenue increased 12% year-on-year from ₹496 crore to ₹554 crore
  • EBITDA margin improved to 27% from 25% in Q1 FY26
  • Profit after tax stood at ₹73 crore for Q1 FY27

Business Performance Updates

  • CRO Business: Maintained strong momentum with 24% year-on-year growth
  • CDMO Business: CMC pipeline strengthened with 33 active commercial molecules and 14 late-phase molecules
  • Customer Mix: 91% pharma and 9% biotech in FY26
  • Global Clients: Trusted by 300+ global clients, including 19 of the top 25 global pharma companies
  • Therapy Areas: Oncology, CNS, Metabolic diseases, Inflammation, Antivirals, Rare diseases

Operational and Strategic Updates

  • New Facilities: Operationalized a new 100,000 sq. ft. R&D facility at Genome Valley, Hyderabad
  • Technology: Successfully executed commercial-scale Photo Flow Chemistry for a late-phase innovator program
  • Platforms: High-Throughput Experimentation (HTE) platform commissioned at Hyderabad R&D campus
  • Sustainability: Achieved EcoVadis Platinum Rating 2026, placing company among top 1% globally for sustainability
  • Digital Transformation: 85% digitization of R&D and manufacturing processes; AI/ML manufacturing process prediction model underway

Capacity and Infrastructure

  • Manufacturing: 700KL cGMP capacity at Bidar site with 80 production trains
  • Global Presence: Facilities in Hyderabad, Bidar, Manchester (UK), and Boston (USA)
  • Employee Strength: 3,800+ global team with 2,000+ in R&D
  • Regulatory Compliance: 100% successful track record of regulatory inspections (USFDA, PMDA)

Guidance and Outlook

  • Maintains long-term revenue growth guidance of 15-20%
  • Maintains EBITDA margin target range of 28-30%
  • Over 90% pipeline visibility on FY27 targets
  • Encouraging traction in FTE-led engagement model